EU-US conference on Long COVID
This online conference aimed to shed light on perspectives for addressing long COVID in the EU and the US. It brought together experts from medical, public health, health economics disciplines, patient organisations and policymakers.
WHO’s Science in 5 : Influenza
How does the vaccine combat the Influenza virus? How does WHO track influenza across the world to decide the composition of the vaccine? Dr Sylvie Briand also explains why we are seeing a spike in respiratory diseases in Science in 5
Universal flu vaccines – soon a reality?
How close are we to a universal flu vaccine? Are universal corona vaccines attainable? What are some of the main challenges facing scientists in their quest to develop these vaccines?
Vaccination of special-risk groups: A toolkit for pharmacists by the International Pharmaceutical Federation (FIP)
It summarises key information, practice guidelines and additional resources in a very practical manner. The Influenza Diabetes Community (IDC) has contributed to the chapter on people living with diabetes.
Policy & Recommendations
Presidency Statement on the Coordination of COVID-19 Travel Measures
On 4 January, the Member States of the EU, in the presence of the Schengen Associated Countries, met in the framework of the Integrated Political Crisis Response (IPCR) to discuss the epidemiological situation in the EU/EEA and developments in China.
Policy & Recommendations
Impact of surge in China COVID-19 cases on epidemiological situation in EU/EEA
ECDC, together with the EU/EEA Member States and the European Commission has increased its monitoring activities and will revise risk assessments and adjust actions if needed.
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years
Immunity from monovalent COVID-19 mRNA vaccination wanes over time. A bivalent COVID-19 mRNA booster dose is recommended for all eligible persons; however, little is known about its effectiveness against COVID-19 hospitalization.
What COVID-19 Vaccines Can and Cannot Do: Setting Realistic Goals in the Current Pandemic
The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication.
The biggest diabetes research stories of 2022
2022 has been a big year for diabetes research, filled with historic moments and world-firsts. Here we take a look back at some of the incredible progress Diabetes UK-funded scientists and diabetes researchers across the globe have been behind this year.
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine
This article assess the effect of RSV fusion protein (F) conformation on B cell responses in a post hoc comparison of samples from the DS-Cav1 [prefusion (pre-F)] and MEDI7510 [postfusion (post-F)] vaccine clinical trials.
Risk of Type 1 Diabetes in Children is Not Increased after SARS-CoV-2 Infection: A Nationwide Prospective Study in Denmark
It has been hypothesized that SARS-CoV-2 infection in children can increase risk of developing type 1 diabetes.